L18I

Overview

L18I is a Bruton's tyrosine kinase ( BTK ) PROTAC degrader that targets wild-type and BTK C481 , and recruits the cereblon E3 ligase to mediate proteasomal degradation. L18I regulates the BCR , TLR , FcγR and NLRP3 inflammasome signaling pathways, inhibits the phosphorylation of PLCγ-2 , ERK1/2 and p38 , and reduces the levels of B cell activation markers CD25 , CD69 and CD86 . L18I downregulates the NF-κB , TNF and TLR signaling pathways, reduces the production of pro-inflammatory cytokines, and decreases immune cell infiltration and immune complex deposition. L18I inhibits the proliferation of BTK -expressing lymphoma cells, induces tumor regression in xenograft models, and exhibits synergistic activity when combined with inhibitors of SYK , PI3K or Lyn . L18I can be used in research related to lupus, diffuse alveolar hemorrhage and B-cell lymphoma . (Pink: Btk ligand ( HY-13036A ); Blue: Cereblon ligand ( HY-43722 ); Black: linker ( HY-41921 )).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Diffuse Large B-cell Lymphoma | Products > Disease Areas > Systemic Lupus Erythematosus | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Btk | Products > Signaling Pathways > Bcr-Abl | Products > Signaling Pathways > Toll-like Receptor (TLR) | Products > Signaling Pathways > Fc Receptor (FcR) | Products > Signaling Pathways > NOD-like Receptor (NLR) | Products > Signaling Pathways > PERK | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > TNF Receptor | Products > Signaling Pathways > PROTACs

Product Information

• Catalog No.: HY-163962
• CAS No.: 2451070-32-7
• Molecular Formula: C47H51N11O8
• Molecular Weight: 897.98
• Purity: 99.43%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (2.78 mM); Clear solution
• Availability: In-stock

Source

Original product source